158 related articles for article (PubMed ID: 18452099)
1. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy.
Oki Y; Kato H; Matsuo K; Kuwatsuka Y; Taji H; Yamamoto K; Kagami Y; Morishima Y
Leuk Lymphoma; 2008 Jul; 49(7):1345-51. PubMed ID: 18452099
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
4. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
Tomita N; Sakai R; Fujisawa S; Fujimaki K; Taguchi J; Hashimoto C; Ogawa K; Yamazaki E; Ishigatsubo Y
Cancer Sci; 2012 Aug; 103(8):1518-23. PubMed ID: 22587388
[TBL] [Abstract][Full Text] [Related]
5. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
6. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
8. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
[TBL] [Abstract][Full Text] [Related]
9. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
10. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D; Asai H; Maeda Y; Shinagawa K; Ikeda K; Yokoyama M; Terui Y; Takeuchi K; Yoshino T; Matsuo K; Hatake K; Tanimoto M
Ann Oncol; 2010 Jun; 21(6):1217-1221. PubMed ID: 19884246
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236
[TBL] [Abstract][Full Text] [Related]
12. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
Advani RH; Chen H; Habermann TM; Morrison VA; Weller EA; Fisher RI; Peterson BA; Gascoyne RD; Horning SJ; ; ;
Br J Haematol; 2010 Oct; 151(2):143-51. PubMed ID: 20735398
[TBL] [Abstract][Full Text] [Related]
13. The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
Tomita N; Suzuki T; Miyashita K; Yamamoto W; Motohashi K; Tachibana T; Takasaki H; Kawasaki R; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Taguchi J; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Motomura S; Kawamoto K; Sone H; Takizawa J
Leuk Lymphoma; 2016 Dec; 57(12):2763-2770. PubMed ID: 27320054
[TBL] [Abstract][Full Text] [Related]
14. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
15. [Clinical outcome of 489 patients with diffuse large B-cell lymphoma and associated factors].
Wen JJ; Zhou JL; Liu ZB; Xu CG
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):519-23. PubMed ID: 24941831
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
18. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab.
Ngo L; Hee SW; Lim LC; Tao M; Quek R; Yap SP; Loong EL; Sng I; Hwan-Cheong TL; Ang MK; Ngeow J; Tham CK; Tan MH; Lim ST
Leuk Lymphoma; 2008 Mar; 49(3):462-9. PubMed ID: 18297522
[TBL] [Abstract][Full Text] [Related]
20. Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.
Green TM; Jensen AK; Holst R; Falgreen S; Bøgsted M; de Stricker K; Plesner T; Mourits-Andersen T; Frederiksen M; Johnsen HE; Pedersen LM; Møller MB
Br J Haematol; 2016 Sep; 174(6):876-86. PubMed ID: 27196819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
